New York State Common Retirement Fund Trims Position in Moderna, Inc. (NASDAQ:MRNA)

New York State Common Retirement Fund decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 4.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 400,732 shares of the company’s stock after selling 20,030 shares during the quarter. New York State Common Retirement Fund owned approximately 0.10% of Moderna worth $26,781,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Stephens Inc. AR grew its position in Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after buying an additional 245 shares during the period. AustralianSuper Pty Ltd boosted its stake in shares of Moderna by 27.0% during the 3rd quarter. AustralianSuper Pty Ltd now owns 14,507 shares of the company’s stock worth $970,000 after acquiring an additional 3,084 shares during the last quarter. Meitav Investment House Ltd. grew its position in shares of Moderna by 96.6% during the 3rd quarter. Meitav Investment House Ltd. now owns 226,903 shares of the company’s stock valued at $15,164,000 after acquiring an additional 111,475 shares during the period. GSB Wealth Management LLC increased its stake in shares of Moderna by 60.8% in the 3rd quarter. GSB Wealth Management LLC now owns 5,292 shares of the company’s stock worth $354,000 after purchasing an additional 2,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Moderna by 67.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 79,611 shares of the company’s stock worth $5,320,000 after purchasing an additional 32,118 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on MRNA shares. The Goldman Sachs Group cut their price target on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a report on Monday, September 16th. Bank of America dropped their price target on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research report on Friday, September 13th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, September 13th. Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Finally, JPMorgan Chase & Co. lowered Moderna from a “neutral” rating to an “underweight” rating and cut their price target for the stock from $88.00 to $70.00 in a research note on Friday, September 13th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average target price of $94.65.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 715 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,184 shares of company stock worth $238,531 over the last ninety days. Company insiders own 15.70% of the company’s stock.

Moderna Price Performance

MRNA stock opened at $54.63 on Monday. Moderna, Inc. has a 52 week low of $52.26 and a 52 week high of $170.47. The firm has a market capitalization of $21.00 billion, a P/E ratio of -3.55 and a beta of 1.69. The company has a fifty day simple moving average of $64.61 and a two-hundred day simple moving average of $100.99. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. During the same quarter last year, the firm earned ($3.62) EPS. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. Analysts anticipate that Moderna, Inc. will post -9.88 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.